G Kobinger

Biography

Dr. Gary Kobinger has obtained his PhD research at the University Montreal which focused on the development of novel gene therapy with HIV-1 proteins and their mechanism in preventing HIV-mediated immunosuppression, where his first landmark scientific contribution was to demonstrate that the HIV Vpr protein could be used as a Trojan horse to deliver amino acid sequences capable of inhibiting HIV replication in CD4+ T cells. Dr, Kobinger’s post-doctoral training was completed at the University of Pennsylvania, where his research was focused on the application of lentiviral, adenoviral and adeno-associated viral vectors for gene therapy and vaccine development. His second landmark scientific contribution was to use pseudotyping as a strategy to target lentiviral vectors to specific cell types in vitro and in vivo). It is worth noting that his initial findings pioneered a since growing field of pseudotyping lentiviral vectors leading to in vivo transduction of organs such as muscle, lungs, brain and liver. It was highlighted as one of the “Best 100 Ideas of 2001” according to the Times Magazine, and to date there are more than 100 peer-reviewed articles published by different research groups around the world. The National Microbiology Laboratory (NML) is one of a handful of laboratories around the world and the only one in Canada that can handle highly infectious containment level 4 (CL-4) pathogens with significant public health impact to which he is now the Chief, Special Pathogens Program. Dr. Kobinger has since made many more important research contributions, with the most significant being the development and characterization of human, chimpanzee and porcine adenoviral vectors for protection against Ebola virus, SARS coronavirus, H5N1 influenza virus and Hantaviruses in different animal models. Dr. Kobinger has published over 60 peer-reviewed manuscripts, 4 book chapters or review articles and is the holder of 9 patents. It should be noted that over 35 of these peer-reviewed articles were published within the past 5 years, which strongly indicates the recent relevance of his work. Dr. Gary Kobinger has obtained his PhD research at the University Montreal which focused on the development of novel gene therapy with HIV-1 proteins and their mechanism in preventing HIV-mediated immunosuppression, where his first landmark scientific contribution was to demonstrate that the HIV Vpr protein could be used as a Trojan horse to deliver amino acid sequences capable of inhibiting HIV replication in CD4+ T cells. Dr, Kobinger’s post-doctoral training was completed at the University of Pennsylvania, where his research was focused on the application of lentiviral, adenoviral and adeno-associated viral vectors for gene therapy and vaccine development. His second landmark scientific contribution was to use pseudotyping as a strategy to target lentiviral vectors to specific cell types in vitro and in vivo). It is worth noting that his initial findings pioneered a since growing field of pseudotyping lentiviral vectors leading to in vivo transduction of organs such as muscle, lungs, brain and liver. It was highlighted as one of the “Best 100 Ideas of 2001” according to the Times Magazine, and to date there are more than 100 peer-reviewed articles published by different research groups around the world. The National Microbiology Laboratory (NML) is one of a handful of laboratories around the world and the only one in Canada that can handle highly infectious containment level 4 (CL-4) pathogens with significant public health impact to which he is now the Chief, Special Pathogens Program. Dr. Kobinger has since made many more important research contributions, with the most significant being the development and characterization of human, chimpanzee and porcine adenoviral vectors for protection against Ebola virus, SARS coronavirus, H5N1 influenza virus and Hantaviruses in different animal models. Dr. Kobinger has published over 60 peer-reviewed manuscripts, 4 book chapters or review articles and is the holder of 9 patents. It should be noted that over 35 of these peer-reviewed articles were published within the past 5 years, which strongly indicates the recent relevance of his work.

Research Interest

Vaccines, Immunology